May 26, 2010 by Brian Orelli, PhDIs Johnson & Johnson a Buy?Let's see what it says to Congress first.
May 25, 2010 by Brian Orelli, PhDGE's Looking Healthy and ImaginativeHappy 1-year birthday, Healthymagination.
May 25, 2010 by Brian Orelli, PhDMedtronic Gets Tossed Out With the BathwaterA bad day to report good news.
May 25, 2010 by Brian Orelli, PhDOrphan Drugs: Small Patient Base, Big OpportunityThis isn't your daddy's Lipitor.
May 21, 2010 by Brian Orelli, PhDAnd You Thought Biotech Was High-Risk, High-RewardLarge clinical trials make cardiovascular drugs risky, but the rewards are there, too.
May 21, 2010 by Brian Orelli, PhDAbbott Learns to Say "Low Margin" in HindiNo matter what country, overpaying isn't a good idea.
May 20, 2010 by Brian Orelli, PhDLipitor Starts Its Fall, Eh?Canadians get a copycat cholesterol drug.
May 20, 2010 by Brian Orelli, PhDFDA Transparency! A Big Win for InvestorsA new disclosure policy could help separate wheat from the chaff.
May 19, 2010 by Brian Orelli, PhDA Potential Blockbuster Bites the Dust. Should You Worry?Making it official doesn't make it exciting.
May 19, 2010 by Brian Orelli, PhDThe Biggest-Little Biotechs in the WorldWith apologies to Reno, Nevada.
May 18, 2010 by Brian Orelli, PhDHealth-Care Reform Hits Drugmakers' (and Your) PocketsSome companies take bigger hits than others.
May 18, 2010 by Brian Orelli, PhDPrice Inflation in Check? Not in This Industry.Drug prices are on the rise. For now.
May 18, 2010 by Brian Orelli, PhDWhat Astellas' Purchase of OSI Means for Biotech InvestorsStop buying for the potential takeout.
May 18, 2010 by Brian Orelli, PhDPfizer Double-DipsIs this the best way to go after multiple indications?
May 12, 2010 by Brian Orelli, PhDIs Merck a Buy?Short term it's hard to say, but for the long term, its pipeline looks strong.
May 12, 2010 by Brian Orelli, PhDPfizer's Backup Backup PlanPfizer adds another PAH drug to its pipeline.
May 11, 2010 by Brian Orelli, PhDAbbott Makes a Push Into Selling LeftoversAn "established product" by any other name is still "old and un-patentable."
May 7, 2010 by Brian Orelli, PhDDrug Companies: Recession-Resistant, but Government-Proof?When the buyer is broke, it's hard to make money.
